ALKBH5 and neoplasm: To therapeutically exploit this axis, they developed folate receptor-targeted exosome–liposome nanoparticles delivering ALKBH5 mRNA, which suppressed tumor growth in preclinical models by restoring ALKBH5 expression and inhibiting the JMJD8/PKM2 metabolic pathway [95].